TEARSHIELD TECHNOLOGY — 2346938
Application number
2346938
Type(s)
Standard Characters
Category
Trademark
CIPO Status
SEARCHED
TM5 status
LIVE/APPLICATION/
Under Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and that this application has been assigned to an examiner.
Filed
2024-08-30
Applicant
Rohto Pharmaceutical Co., Ltd.
8-1, Tatsuminishi 1 Chome, Ikuno-ku, Osaka-shi
Osaka 544-8666,
JAPAN
Agent
ERIN MCEWEN
NELLIGAN O'BRIEN PAYNE LLP
50 O'Connor Street
Suite 300
Ottawa,
ONTARIO K1P6L2
Documents
Index headings
- TEARSHIELD TECHNOLOGY
- TEAR SHIELD
Goods (Nice class & Statement)
- 5
- (1) Absorbent cotton; adhesive plasters; adhesive tapes for medical purposes; bandages for dressings; beverages for babies; breast-nursing pads; collyrium; cotton swabs for medical use; diaper covers; disinfectants for contact lenses; ear bandages; empty capsules for pharmaceuticals; eye drops; eyepatches for medical purposes; fly catching paper; food for babies; gauze for dressings; lacteal flour for babies; liquid bandages; medicated eye-washes; menstruation bandages; menstruation tampons; mothproofing paper; reagent paper for medical purposes; sanitary napkins; sanitary panties; solutions for contact lenses
- 5
- (2) Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for treating sensory organ disorders; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical anti-viral agents; Pharmaceutical anti-inflammatories; Pharmaceutical preparations for the relief of pain; Pharmaceutical preparations for use in immunotherapies; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in cell therapy; Human pharmaceutical vaccines; Pharmaceutical preparations for the treatment of central nervous system (CNS) diseases; Pharmaceutical preparations for the treatment of mental health disorders; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries, namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of hepatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of renal diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the respiratory system; Pharmaceutical preparations and substances for use in urology; Dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations and compositions for the treatment and prevention of cancer; Pharmaceutical preparations for the prevention and treatment of muscular atrophy; Pharmaceutical preparations for the treatment of dental and oral diseases; Pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; Pharmaceutical preparations for the prevention and treatment of cerebrovascular diseases; Pharmaceutical preparations for the treatment of varicose veins; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Human pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; Pharmaceutical preparations and substances for the treatment of diseases and disorders of the peripheral nervous system, namely cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies and plexopathies; Pharmaceutical preparations for the treatment of brain diseases and disorders, namely epilepsy, Alzheimer's disease, cerebral palsy, Parkinson's disease and multiple sclerosis; Pharmaceutical preparations for the treatment and prevention of dementia; Neurological and psychological pharmaceutical preparations for the treatment of chemical dependency; Pharmaceutical preparations for the treatment of sports injuries, namely injured and torn skin, muscle, ligaments and bone; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for human use, namely pharmaceutical antibodies for use as anti-infectives and anti-inflammatories; Cleaning solutions for contact lenses; Contact lens wetting solutions; Solutions for neutralizing contact lenses; Rinsing, cleaning, preserving solution for contact lenses; Eyewashes that are used while wearing contact lenses; Eye drops for use while wearing contact lenses; Contact lens solutions for cleaning, disinfecting and preserving purposes; Reagent paper for medical and veterinary purposes; Dental preparations for disclosing plaque; Dental wax; Materials for dental fillings and dental impressions; Adult diapers; Babies' diapers; Dietary supplements for the treatment of eye conditions; Diabetic fruit juice beverages adapted for medical purposes; Dietetic beverages for babies adapted for medical purposes; Effervescent tablets and powders used to make beverages to support digestive health and general health and well-being; Effervescent tablets and powders used to make electrolyte replacement beverages for medical purposes; Malted milk beverages for medical purposes; Medicated beverages in the nature of dietary supplements for colon detoxification; Medicated beverages in the nature of dietary supplements for liver detoxification; Medicated beverages in the nature of botanical supplements for the treatment of mental health disorders; Medicinal beverages for the treatment of gluten intolerance and celiac disease; Nutraceutical food and beverages for general health and well-being; Nutritional supplement meal replacement beverages containing vitamins and minerals; Dietetic food and substances adapted for medical and veterinary use for general health and well-being; Dietary supplements for animals for general health and well-being; Dietary supplements for animals, namely antioxidants; Dietary supplements for animals containing cannabinoids for medicinal purposes; Dietary supplements for animals containing cannabis derivatives for medicinal purposes; Mineral dietary supplements for animals; Feed supplements for veterinary purposes; Vitamin and mineral supplements for pets; Vitamin supplements for animals;
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2024-08-30 | ||
| Created | 2024-08-30 | ||
| Formalized | 2024-08-30 | ||
| Pre-Assessment Letter Sent | 2024-09-12 | Multiple Reasons | |
| Search Recorded | 2025-09-29 | ||
| Examiner's First Report | 2025-09-29 | 2026-03-29 |